Bernard Fisher (scientist)

Error creating thumbnail:

Nci-vol-8226-300 bernard fisher

Bernard Fisher (August 23, 1918 – October 16, 2019) was an American surgeon and a pioneer in the field of breast cancer research. His work fundamentally changed the understanding and treatment of breast cancer, moving away from radical mastectomy towards more conservative treatments that have significantly improved outcomes for patients.

Early Life and Education

Bernard Fisher was born in Pittsburgh, Pennsylvania. He pursued his undergraduate education at the University of Pittsburgh, where he also received his medical degree. After completing his medical education, Fisher served in the United States Army during World War II, where he was stationed in Europe.

Career

After the war, Fisher returned to the University of Pittsburgh, where he began his career in medical research. He initially focused on liver regeneration but shifted his focus to breast cancer in the 1950s. Fisher's interest in breast cancer research was partly due to the high mortality rates associated with the disease and the radical treatment approaches that were prevalent at the time.

Fisher challenged the then-standard practice of radical mastectomy, a procedure that involved the removal of the entire breast, underlying chest muscle, and lymph nodes of the armpit. He hypothesized that breast cancer was a systemic disease rather than a locally contained one, which meant that less invasive surgeries could be equally effective.

Key Contributions

Fisher's most significant contribution to breast cancer treatment was his leadership in conducting large-scale, randomized clinical trials through the National Surgical Adjuvant Breast and Bowel Project (NSABP). These studies demonstrated that lumpectomy (removal of the tumor and a small margin of surrounding tissue) followed by radiation therapy was as effective as radical mastectomy for many women with early-stage breast cancer. This finding led to a paradigm shift in the treatment of breast cancer, significantly reducing the physical and psychological impact of breast cancer surgery.

Fisher also contributed to the understanding of the role of hormones in breast cancer growth and the effectiveness of tamoxifen, a drug that blocks estrogen receptors on breast cancer cells, in reducing recurrence rates.

Awards and Honors

Throughout his career, Fisher received numerous awards and honors for his contributions to medical science and breast cancer research, including the Lasker Award for Clinical Medical Research and the National Medal of Science.

Legacy

Bernard Fisher's work has had a lasting impact on the field of breast cancer treatment, leading to more conservative surgical approaches and the development of treatments that target the disease more precisely. His emphasis on evidence-based medicine and the use of clinical trials to guide treatment decisions has influenced not only breast cancer care but also the broader field of oncology.

Death

Bernard Fisher passed away on October 16, 2019, at the age of 101. His legacy continues through the ongoing work of the NSABP and the countless lives saved through the treatment approaches he pioneered.